Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Single-Arm Study of Trastuzumab Emtansine in Patients With HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Received At Least One Prior Chemotherapy Regimen

NCT02289833 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02289833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02289833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Single-Arm Study of Trastuzumab Emtansine in Patients With HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Received At Least One Prior Chemotherapy Regimen
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
December 15, 2014
Completion date
August 20, 2018
Enrollment
49 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer